期刊文献+

慢性乙型肝炎药物治疗研究进展 被引量:8

下载PDF
导出
摘要 乙型肝炎病毒(hepatitisBvirus,HBV)感染已成为危害人类健康的重要疾病。慢性乙型肝炎治疗的总体目标就是最大限度地长期抑制HBV,减轻肝细胞炎症坏死及肝纤维化,延缓和减少肝脏失代偿、肝硬化、HCC及其并发症的发生,从而改善生活质量和延长存活时间。慢性乙型肝炎治疗主要包括抗病毒、免疫调节、抗炎、抗氧化、抗纤维化和对症治疗,其中抗病毒治疗是关键。本文通过收集文献,对治疗乙肝药物的作用机制、应用情况做一综述,期望能更好地指导临床医生用药。
出处 《中国医学创新》 CAS 2011年第32期161-163,共3页 Medical Innovation of China
  • 相关文献

参考文献27

  • 1Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg posi- tive chronic hepatitis reduces progression to cirrhosis and hepatocellu- lar carcinoma. J Hepatol,2007,46( 1 ) :45 - 52.
  • 2Chen YC, Chu CM, Yeh CT, et 81. Natural course following the on- set of cirrhosis in patients with chronic hepatitis B : a long - term fol- low - up study. Hepatol Int,2007,1 ( 1 ) :267 - 273.
  • 3Hsu YS, Chien RN, Yeh CT, et 81. Long - term outcome after spon- taneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, 2002,35 ( 6 ) : 1522 - 1527.
  • 4Chu CM, Liaw YF. Hepatitis B virus - related cirrhosis : natural his- tory and treatment. Semin Liver Dis ,2006,26 (2) :142 -152.
  • 5Chen C J, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JA- MA ,2006,295 ( 1 ) :65 - 73.
  • 6Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 2002, 347 (3): 168 - 174.
  • 7Tai DI, Chen CH, Chang T'I', et al. Eight- year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role ofviral infection. J Gastroenterol Hepatol,2002,17 (6) :682 - 689.
  • 8中国疾病预防控制中心.乙型肝炎疫苗儿童计划免疫技术管理规程(试行)[Z].,2002..
  • 9Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa- 2a (40 kD) with or without lamivudine in Asian patients with HBeAg - positive and HBeAg - negative chronic hepati- tis B. Hepatol Int,2008,2( 1 ) :102 - 110.
  • 10Chan HL, Leung NW, Hui AY, et al. A randomized, contr] trim of eombination therapy for ehronie hepatitis B : comparing I~ lated interferon - alpha2b and Ann Intern Med ,2005,142 (4) lamivudine with lamivudine all I :240 - 250. I.

二级参考文献44

共引文献593

同被引文献60

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部